Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 3/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | SLC22A3 | O75751 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA6 | P23280 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | POU5F1 | Q01860 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiotidine SCHEMBL9436849 | 0.99 | HRH2 (0.70) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| SCHEMBL12648668 | 0.87 | HRH2 (0.67) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| SCHEMBL10367343 | 0.87 | HRH2 (0.77) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| SCHEMBL10675315 | 0.85 | HRH2 (0.51) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| SCHEMBL10675308 | 0.85 | HRH2 (0.51) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| Tiotidine SCHEMBL7574356 | 0.83 | HRH2 (1.00) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| SCHEMBL11353506 | 0.83 | CYP3A4 (0.48) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| Tiotidine SCHEMBL9334802 | 0.82 | CYP3A4 (0.48) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| Tiotidine SCHEMBL10425944 | 0.82 | CYP3A4 (0.48) | HRH2MAPTCYP3A4CYP2D6SLC22A2 | |
| SCHEMBL10425975 | 0.79 | ACHE (0.59) | HRH2MAPTCYP3A4CYP2D6SLC22A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1699 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630401-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | Rutgers, the State University of New Jersey (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250177398-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-06-05 | — | — | US | claimed |
| US-12263168-B2 | Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-04-01 | — | — | US | claimed |
| US-20250099498-A1 | STRONTIUM BASED COMPOSITIONS AND FORMULATIONS FOR PAIN, PRURITUS, AND INFLAMMATION | GALLEON LABS LLC (US) | 2025-03-27 | — | — | US | claimed |
| US-20250085273-A1 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2025-03-13 | — | — | US | claimed |
| US-20240415789-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | TONIX PHARMA LIMITED (IE) | 2024-12-19 | — | — | US | claimed |
| US-12121536-B2 | Strontium based compositions and formulations for pain, pruritus, and inflammation | GALLEON LABS LLC (US) | 2024-10-22 | — | — | US | claimed |
| EP-4412602-A1 | CYCLOBENZAPRINE FOR TREATMENT OR PREVENTION OF SEXUAL DYSFUNCTION ASSOCIATED WITH MENTAL HEALTH CONDITIONS IN FEMALE PATIENTS | Tonix Pharmaceuticals Holding Corp. (US) | 2024-08-14 | — | — | EP | claimed |
| WO-2024124023-A2 | CARBONIC ANHYDRASE ENZYME INHIBITORS AND METHODS OF USE THEREOF | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-06-13 | — | — | WO | claimed |
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | claimed |
| US-5538737-A | WATER-IN-OIL EMULSION IN CAPSULE FORM | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1996-07-23 | — | — | US | claimed |
| WO-1996018605-A1 | ACYLOXYISOPROPYL CARBAMATES AS PRODRUGS FOR AMINE DRUGS | MERCK & CO., INC. (US) | 1996-06-20 | — | — | WO | claimed |
| WO-1996016640-A1 | ORAL COMPOSITIONS OF H2-ANTAGONISTS | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1996-06-06 | — | — | WO | claimed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| US-5352688-A | Methods for the treatment of bradyphrenia in parkinson's disease | THE MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1994-10-04 | — | — | US | claimed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | claimed |
| CN-1082400-A | The purposes of H-2 antagonist for treating gingivitis | PROCTER & GAMBLE (US) | 1994-02-23 | — | — | CN | claimed |
| WO-1993020815-A1 | USE OF H-2 ANTAGONISTS FOR TREATMENT OF GINGIVITIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-28 | — | — | WO | claimed |
| US-5070101-A | Method and pharmaceutical composition for the treatment of schizophrenia | MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK (US) | 1991-12-03 | — | — | US | claimed |
| US-4353902-A | HISTAMINE H2 ANTAGONIST | SMITHKLINE CORPORATION (US) | 1982-10-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12263168-B2 | Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation | CA2, CMA1, CPA3 | HRH2 62/4885MAPT 4350/4885CYP3A4 1824/4885 |
| US-20250177398-A1 | CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION | CA2, CMA1, CPA3 | HRH2 62/4885MAPT 4350/4885CYP3A4 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.